Xarelto Denied Expanded Approval by FDA
Xarelto, which has been introduced along with Pradaxa as the next generation of blood thinner medications in recent years, has been denied by federal regulators as a means to prevent life-threatening blood clots. Johnson & Johnson, the maker of Xarelto, had previously requested that the Food and Drug Administration (FDA) consider expanding the approval of the drug so it could act as a preventative measure against blood clots in patients who have been diagnosed with acute